Loading...
Most studies of hormone therapy (HT) and ovarian cancer risk have been too small to permit definitive evaluation of HT's effects. Now, investigators have aggregated individual participant data from all available epidemiologic studies (17 prospective and 35 retrospective; 21,488 postmenopausal ovarian cancer cases) to assess HT's impact on ovarian cancer risk. To minimize bias and address timing of HT use, the authors focused on prospective studies that included data on duration and recency of use (12,100 cases; mean year of diagnosis, 2001; 55% of participants had used HT for a median duration of 6 years). Analyses were stratified by study center, age, and body-mass index and adjusted for parity, prior use of oral contraceptives, and age at…